ReviewInternational journal of chronic obstructive pulmonary disease2008
Role of macrolide therapy in chronic obstructive pulmonary disease.
Review in International journal of chronic obstructive pulmonary disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis.Pediatric research · 2024Pooled it
- Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2018Pooled it
- A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2023Trial
- A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.Journal of negative results in biomedicine · 2015Trial
- Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial.Respiratory research · 2013Trial
- Azithromycin for prevention of exacerbations of COPD.The New England journal of medicine · 2011Trial
- Review
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- Management of Asthma and COPD Exacerbations in Adults in the ICU.CHEST critical care · 2025Article
- Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions.International journal of molecular sciences · 2025Review
- Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations.The Journal of antimicrobial chemotherapy · 2025Article
- Management of Refractory Chronic Obstructive Pulmonary Disease: A Review.Life (Basel, Switzerland) · 2024Review
- Understanding the molecular regulatory mechanisms of autophagy in lung disease pathogenesis.Frontiers in immunology · 2024Review
- Acute exacerbation of interstitial lung disease in the intensive care unit: Principles of diagnostic evaluation and management.World journal of critical care medicine · 2023Review
- Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations.Frontiers in medicine · 2023Article
- Respiratory Viral and Bacterial Exacerbations of COPD-The Role of the Airway Epithelium.Cells · 2022Review
- A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.European journal of pharmacology · 2021Review
- Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability worldwide. The Global Burden of Disease study has concluded that COPD will become the third leading cause of death worldwide by 2020, and will increase its ranking of disability-adjusted life years lost from 12th to 5th. Acute exacerbations of COPD (AECOPD) are associated with impaired quality of life and pulmonary function. More frequent or severe AECOPDs have been associated with especially markedly impaired quality of life and a greater longitudinal loss of pulmonary function. COPD and AECOPDs are characterized by an augmented inflammatory response. Macrolide antibiotics are macrocyclical lactones that provide adequate coverage for the most frequently identified pathogens in AECOPD and have been generally included in published guidelines for AECOPD management. In addition, they exert broad-ranging, immunomodulatory effects both in vitro and in vivo, as well as diverse actions that suppress microbial virulence factors. Macrolide antibiotics have been used to successfully treat a number of chronic, inflammatory lung disorders including diffuse panbronchiolitis, asthma, noncystic fibrosis associated bronchiectasis, and cystic fibrosis. Data in COPD patients have been limited and contradictory but the majority hint to a potential clinical and biological effect. Additional, prospective, controlled data are required to define any potential treatment effect, the nature of this effect, and the role of bronchiectasis, baseline colonization, and other cormorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.